- $1.40bn
- $1.37bn
- $201.61m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 35.13 | ||
| PEG Ratio (f) | 0.53 | ||
| EPS Growth (f) | 192.22% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 19.08 | ||
| Price to Tang. Book | 19.08 | ||
| Price to Free Cashflow | 58.73 | ||
| Price to Sales | 6.93 | ||
| EV to EBITDA | 76.44 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 5.31% | ||
| Return on Equity | 4.45% | ||
| Operating Margin | 3.05% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 79.56 | 111.7 | 150.35 | 174.53 | 201.61 | 236.33 | 274.73 | 27.85% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -67.91 | n/a | n/a | n/a | -57.73 | +826.54 | +31.43 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Enfusion, Inc. provides a software-as-a-service (SaaS) platform for investment managers. The Company, through its software, analytics, and middle/back-office managed services, creates enterprise-wide cultures of real-time, data-driven intelligence and collaboration. Its cloud-native, purposefully designed, end-to-end solution gives clients the ability to access and analyze investment information in real time, perform complex calculations quickly and interact with markets electronically, adding up to making better informed investment decisions and actions. Its solutions include a portfolio management system (PMS), an order and execution management system (OEMS), an accounting/general ledger system, an Enfusion analytics system and offer technology-powered, managed services. Its solution is utilized by a variety of users, including portfolio managers, traders, compliance officers, operational support staff and executive management.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 2nd, 2007
- Public Since
- October 21st, 2021
- No. of Shareholders
- 10
- No. of Employees
- 1,143
- Sector
- Software & IT Services
- Industry
- Technology
- Exchange
New York Stock Exchange- Shares in Issue
- 129,847,448
- Address
- 125 South Clark Street, Suite 750, CHICAGO, 60603
- Web
- Phone
- +1 3122539800
- Auditors
- Ernst & Young LLP
Upcoming Events for ENFN
Enfusion Inc Annual Shareholders Meeting
Q2 2025 Enfusion Inc Earnings Release
Similar to ENFN
A10 Networks
New York Stock Exchange
Accenture
New York Stock Exchange
ACV Auctions
New York Stock Exchange
Alibaba Holding
New York Stock Exchange
Alight
New York Stock Exchange
FAQ
What is the Enfusion share price?
As of Today at 20:26 UTC, shares in Enfusion are trading at $10.76. This share price information is delayed by 15 minutes.
How has the Enfusion share price performed this year?
Shares in Enfusion last closed at $10.76 and the price had moved by +15.7% over the past 365 days. In terms of relative price strength the Enfusion share price has outperformed the S&P500 Index by +8.79% over the past year.
What are the analyst and broker recommendations for Enfusion?
The overall consensus recommendation for Enfusion is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Enfusion dividend yield?
Enfusion does not currently pay a dividend.
Does Enfusion pay a dividend?
Enfusion does not currently pay a dividend.
When does Enfusion next pay dividends?
Enfusion does not currently pay a dividend.
How do I buy Enfusion shares?
To buy shares in Enfusion you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Enfusion?
As of the previous close price of $10.76, shares in Enfusion had a market capitalisation of $1.40bn.
Where are Enfusion shares listed?
Here are the trading details for Enfusion:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: ENFN
What kind of share is Enfusion?
Based on an overall assessment of its quality, value and momentum Enfusion is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Enfusion share price forecast for 2025?
The analyst consensus target price for shares in Enfusion is $10.93. That is 1.58% above the last closing price of $10.76.
Analysts covering Enfusion currently have a consensus Earnings Per Share (EPS) forecast of $0.28 for the next financial year.
Find out moreWhat is the trend in the Enfusion share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Enfusion. Over the past six months, its share price has outperformed the S&P500 Index by +36.11%.
As of the last closing price of $10.76, shares in Enfusion were trading +9.44% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Enfusion PE Ratio?
The Enfusion PE ratio based on its reported earnings over the past 12 months is 35.13. The shares last closed at $10.76.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Enfusion?
We do not have data on Enfusion's directors